Could a Lab-Made protein help fight HIV-Linked cancer?
NCT ID NCT07308886
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This study tests a lab-made protein called CYT107 in 55 adults with HIV and Kaposi sarcoma, a cancer linked to a weakened immune system. The protein is given as weekly shots for up to 4 weeks to try to increase T cells and shrink tumors. Researchers will monitor how well it works and any side effects over 3 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CYT107 (a lab-made human protein that may boost the immune system)
What this could lead to
If it works, this could offer a new way to treat Kaposi sarcoma in people with HIV by strengthening the immune system to fight the cancer.
What could go wrong
This is a small, early-phase trial with only 55 participants, so results may not apply to everyone. The treatment may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.